SRRK Scholar Rock Holding Corporation Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
15:34
Sep 17
Sep 17
SRRK drug too costly for GLP-1 combo use
The author argues the biggest obstacle for SRRK's drug in muscle wasting alongside GLP-1s is cost: at $310k per year (~$26k/month) versus GLP-1s at $250-$500/month, patients already drop off GLP-1s at the lower price. The mechanism is that payer and patient affordability will prevent adoption alongside GLP-1s unless the price falls substantially. No specific catalyst or timeframe is given; the main risk is that pricing or reimbursement could improve.
HIGH
08:48
Sep 15
Sep 15
SRRK buyout target for LLY or NVO
The author owns SRRK and believes it will be acquired by either LLY or NVO because of its muscle preservation function when used alongside GLP-1 drugs. The mechanism is strategic fit: GLP-1 makers may want to add a muscle-preserving agent to their obesity franchises, making SRRK an attractive acquisition target. No specific catalyst or timeframe is given, and the main risk is that no buyout materializes.
HIGH
21:42
Sep 11
Sep 11
The author congratulates Rock Scholars on a milestone but provides no directional view.
The author congratulates Rock Scholars on a milestone but provides no directional view or position on Scholar Rock, so the ticker is only worth indexing.
LOW
13:09
Aug 17
Aug 17
Author shares a net conviction chart listing multiple biotech tickers without explicit position.
Author shares a net conviction chart listing multiple biotech tickers without explicit position language, so these are indexed as watch rather than directional calls.
LOW
12:32
Aug 17
Aug 17
Notes Q2 aggregate fund value decrease
Notes the stock saw one of the largest aggregate value decreases across 93 funds in Q2 13F filings.
MED
21:53
Mar 19
Mar 19
The author correctly predicted the failure of Roche's MANATEE study.
The author correctly predicted the failure of Roche's MANATEE study, highlighting a potential shift in the competitive landscape for myostatin drugs.
HIGH
About SRRK Investor Commentary
Across the available history and selected sources, Buzzberg tracks SRRK (Scholar Rock Holding Corporation) across 3 sources: 1 bullish vs 1 bearish calls from 4 authors. Historical directional balance: 0% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 6 total trade ideas tracked. Past 7 days, before deduplication: 1 bullish, 1 bearish. Latest voices: u/Weekly-Barracuda-494, u/Cubyface, A May MD.